ARCHIVES

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

This article is from The Cancer Letter archive.

Vol. 32 No. 01 | January 13, 2006

Download PDF Visit The Full Archive

Related Articles

Clinical Trials: Breast Cancer Prevention Trial requires Fewer Participants, NCI Says

September 6, 1996

NCI advisors approve new grants programs. NCI funds consortium of cohorts. Funding opportunities listed.

August 1, 2003

DePinho’s Handling Of MD Anderson Tenure Dispute Triggers Formal Investigation by AAUP

July 18, 2014

Orphan Designation Granted To Advaxis HPV Immunotherapy

May 30, 2014

Cancer Letter Adds Associate Editor

July 19, 1985

SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma

September 29, 2006